ALFA Finder| Revenue growth | 17% CAGR (FY11-FY26); FY26 sales Rs 582 Bn. |
|---|---|
| Margins | EBITDA margin improved from 26.9% (FY22) to 30.3% (FY26). |
| Demand visibility | Strong across chronic segments and Innovative Medicines portfolio. |
| Management confidence | High; citing 'Strong balance sheet' and 'Best-in-class profitability'. |
Growth
FY26 sales reached Rs 582 Bn, with a CAGR of 17% (FY11-FY26). EBITDA margin expanded to 30.3% in FY26.
Outlook
Targeting increased contribution from Innovative Medicines and complex products. R&D investment stands at 6.1% of sales.
Risks
Exposure to US generics market dynamics and ongoing global regulatory compliance across 40 manufacturing facilities.
Last quarter's promises, checked
Delivered
- High single-digit FY27 revenue growth → delivered 10.1% Q1 growth (= BEAT)
- Organon closing by early 2027 → on track with shareholder approval (= BEAT)
- Innovative medicine growth → delivered $351M, up 12.8% (= BEAT)
Partly delivered
- R&D spend normalization → Q1 tracking lower at 5.4% of sales (= PARTIAL)
Missed
- EBITDA margin improvement → delivered 28.9% vs higher FY26 base (= MISS)
Investor Presentation filed with NSE, NSE: SUNPHARMA. Summary written with AI assistance from the document.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,902.30
- Market cap
- ₹4,56,426 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 41.6×Sector 43.8×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Price Movement Clarification
Sun Pharma said a 30 October 2026 news report concerned August 2026 developments, not new events. It confirmed no undisclosed material information explains the share price movement.
Sun Pharmaceutical Industries Annual General Meeting
Sun Pharma's postal ballot passed all seven special resolutions, including ESOP 2026 approval and borrowing and security limits. No monetary transaction is stated.
Sun Pharmaceutical Industries Earnings Call Transcript: Key Takeaways
Sun Pharma delivered resilient double-digit revenue growth despite U.S. specialty headwinds, masking underlying margin pressure from lower Lenalidomide sales.
Sun Pharmaceutical Industries Other Announcement
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Q2 FY27 Results: Net Profit ₹1,995 Cr, Down 36.2% YoY
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹16,199 Cr (+11.9% YoY) and net profit of ₹1,995 Cr (-36.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,995 Cr · -36.2% YoY
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.